PR Newswire Clinical TrialsOriginal article
Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
ASC30ASC39ASC30_39 FDCPositive
AI Analysis
Summary
Ascletis announced a fixed-dose combination of ASC30 (GLP-1R agonist) and ASC39 (amylin receptor agonist) that demonstrated comparable pharmacokinetics to respective monotherapies in a preclinical dog study.
Outcome Details
Fixed-dose combination demonstrated comparable pharmacokinetics to monotherapies in preclinical dog study
Importance:3/10
Sentiment:
0.60
GLP-1R agonistamylin receptor agonistfixed-dose combinationoral small moleculepreclinicalpharmacokinetics
Read the original article
Published by PR Newswire Clinical Trials on April 7, 2026 11:00 AM